Ju-Fang Shi

International trends in primary liver cancer incidence from 1973 to 2007

BackgroundPrimary liver cancer (PLC) is a common cancer worldwide, especially in developing countries. Several previous studies using different datasets have summarized PLC incidence rates and trends in different populations. However, with changes in exposure to risk factors and the implementation of preventive measures, the epidemiology of PLC worldwide may have changed.MethodsWe extended the analyses using the latest data from Cancer Incidence in Five Continents over the 35-year period 1973–2007 from 24 populations in Americas, Asia, Europe and Oceania using Joinpoint regression analysis. We examined age-standardized rates (ASRs) of PLC by histologic subtypes for both males and females in 24 populations during the period 2003–2007.ResultsWe found that during the period 2003–2007, the highest ASRs for PLC were observed in some Asian populations, ranging from 19.0 to 26.7 per 100,000 in males and 4.8 to 8.7 per 100,000 in females. The international trends between 1973 and 2007 showed that ASRs for PLC were declining in several Asian populations. In contrast, ASRs for PLC were increasing in some European, American and Oceanian populations.ConclusionsAlthough the reasons were not fully clear for these trends, public health measures in Asian populations and HCV transmission in European, American and Oceanian populations were likely to have contributed to these patterns. Meanwhile, other possible risk factors such as the consumption of alcohol, obesity, and nonalcoholic fatty liver disease should also be concerned for the burden of PLC.

Expenditure and financial burden for common cancers in China: a hospital-based multicentre cross-sectional study

BACKGROUNDnComprehensive health economic evaluation, a key component of the Cancer Screening Program in Urban China (CanSPUC), was expected to support government policy-making on screening initiatives for common cancers (lung, breast, colorectal, oesophageal, liver, and stomach cancer) in urban China. Estimation of expenditure for cancer diagnosis and treatment from a societal perspective was an essential component. The aim of this study was to estimate direct medical and non-medical expenditure and to discern the resultant financial burden.nnnMETHODSnA multicentre cross-sectional survey of patients with target cancers or precancerous lesions was conducted in 37 tertiary hospitals in 13 provinces across China, from 2012 to 2014. Each patient was interviewed with a structured questionnaire for sociodemographic, clinical, and expenditure information. Expenditure data was converted to 2014 values and presented as US

Quality-of-life and health utility scores for common cancers in China: a multicentre cross-sectional survey

. Expenditure and financial burden were quantified as a whole and by subgroups.nnnFINDINGSnOf the included 14u2008594 patients with cancer (mean age 56·7 years, 58% male), annual household income was

International trends in lung cancer incidence from 1973 to 2007

8607. Mean expenditure per patient was

Medical expenditure for esophageal cancer in China: a 10-year multicenter retrospective survey (2002–2011)

9739 (95% CI 9612-9866), and non-medical expenditure accounted for 9·3%. Expenditure per patient with colorectal, oesophageal, lung, stomach, liver or breast cancer was

Breast cancer risk factors and mammographic density among high-risk women in urban China

10u2008978 (10u2008636-11u2008321),

Health-related quality of life and utility scores of patients with breast neoplasms in China: A multicenter cross-sectional survey

10u2008506 (10u2008199-10u2008813),

Medical expenses of urban Chinese patients with stomach cancer during 2002–2011: a hospital-based multicenter retrospective study

9970 (9664-10 276),

Medical and non‐medical expenditure for breast cancer diagnosis and treatment in China: a multicenter cross‐sectional study

9891 (9606-10u2008176),

Adherence to screening colonoscopy and its influencing factors in China: a multicentre population-based cross-sectional study

8668 (8358-8977) and